Molecular and cell-based therapies for muscle degenerations: A road under construction

Frontiers in Physiology

Volumn 5 APR, Issue , 2014, Pages

  Berardi, Emanuele ^a,b   Annibali, Daniela ^c   Cassano, Marco ^b,d   Crippa, Stefania ^b,e   Sampaolesi, Maurilio ^a,b,f  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Interuniversity Institute of Myology   (Italy)

^c Vlaamse Institute voor Biotechnologie   (Belgium)

^d EPFL   (Switzerland)

^e University of Lausanne Medical Center   (Switzerland)

^f UNIVERSITY OF PAVIA   (Italy)

Author keywords

Cachexia; Gene and cell therapies; Molecular treatments; Muscle degeneration; Stem cells

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CORTICOSTEROID; CYTOKINE ANTIBODY; DYSTROPHIN; ETEPLIRSEN; FENOFIBRATE; GHRELIN; INDOMETACIN; INTERLEUKIN 6; ISOSORBIDE DINITRATE; METHYLPREDNISOLONE; MICRORNA; MYOSTATIN; SIMVASTATIN; UNTRANSLATED RNA;

ARTIFICIAL VENTILATION; BREATHING MUSCLE; CACHEXIA; CELL DIFFERENTIATION; CELL FATE; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; GENE THERAPY; HUMAN; MOLECULAR BIOLOGY; MOLECULAR THERAPY; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; MYOBLAST; MYOSITIS; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PHYSICAL CAPACITY; PLURIPOTENT STEM CELL; REGULATORY MECHANISM; REVIEW; SARCOPENIA; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; WALKING;

EID: 84901065506     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2014.00119     Document Type: Review

References (151)

1. Aartsma-Rus, A., Kaman, W. E., Weij, R., Den Dunnen, J. T., Van Ommen, G. J., and Van Deutekom, J. C. (2006). Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons. Mol. Ther. 14, 401-407. doi: 10.1016/j.ymthe.2006.02.022
2. Abdel-Hamid, H., and Clemens, P. R. (2012). Pharmacological therapies for muscular dystrophies. Curr. Opin. Neurol. 25, 604-608. doi: 10.1097/Wco.0b013e328357f44c
3. Apparailly, F., Millet, V., Noel, D., Jacquet, C., Sany, J., and Jorgensen, C. (2002). Tetracycline-inducible interleukin-10 gene transfer mediated by an adeno-associated virus: application to experimental arthritis. Hum. Gene Ther. 13, 1179-1188. doi: 10.1089/104303402320138961
4. Awaya, T., Kato, T., Mizuno, Y., Chang, H., Niwa, A., Umeda, K., et al. (2012). Selective development of myogenic mesenchymal cells from human embryonic and induced pluripotent stem cells. PLoS ONE 7:e51638. doi: 10.1371/journal.pone.0051638
5. Barberi, T., Bradbury, M., Dincer, Z., Panagiotakos, G., Socci, N. D., and Studer, L. (2007). Derivation of engraftable skeletal myoblasts from human embryonic stem cells. Nat. Med. 13, 642-648. doi: 10.1038/nm1533
6. Barton-Davis, E. R., Cordier, L., Shoturma, D. I., Leland, S. E., and Sweeney, H. L. (1999). Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J. Clin. Invest. 104, 375-381. doi: 10.1172/JCI7866
7. Beauchamp, J. R., Heslop, L., Yu, D. S., Tajbakhsh, S., Kelly, R. G., Wernig, A., et al. (2000). Expression of CD34 and Myf5 defines the majority of quiescent adult skeletal muscle satellite cells. J. Cell Biol. 151, 1221-1234. doi: 10.1083/jcb.151.6.1221
8. Benedetti, S., Hoshiya, H., and Tedesco, F. S. (2013). Repair or replace? Exploiting novel gene and cell therapy strategies for muscular dystrophies. FEBS J. 280, 4263-4280. doi: 10.1111/febs.12178
9. Berardi, E., Pues, M., Thorrez, L., and Sampaolesi, M. (2012). miRNAs in ESC differentiation. Am. J. Physiol. Heart Circ. Physiol. 303, H931-H939. doi: 10.1152/ajpheart.00338.2012
10. Bhagavati, S., and Xu, W. (2005). Generation of skeletal muscle from transplanted embryonic stem cells in dystrophic mice. Biochem. Biophys. Res. Commun. 333, 644-649. doi: 10.1016/j.bbrc.2005.05.135
11. Blake, D. J., Weir, A., Newey, S. E., and Davies, K. E. (2002). Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev. 82, 291-329. doi: 10.1152/physrev.00028.2001
12. Bodine, S. C., Latres, E., Baumhueter, S., Lai, V. K. M., Nunez, L., Clarke, B. A., et al. (2001). Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294, 1704-1708. doi: 10.1126/science.1065874
13. Bonifati, M. D., Ruzza, G., Bonometto, P., Berardinelli, A., Gorni, K., Orcesi, S., et al. (2000). A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 23, 1344-1347. doi: 10.1002/1097-4598(200009)23:9<1344::AID-MUS4>3.0.CO;2-F
14. Brack, A. S., and Rando, T. A. (2012). Tissue-specific stem cells: lessons from the skeletal muscle satellite cell. Cell Stem Cell 10, 504-514. doi: 10.1016/j.stem.2012.04.001
15. Bruera, E. (1997). ABC of palliative care. Anorexia, cachexia, and nutrition. BMJ 315, 1219-1222. doi: 10.1136/bmj.315.7117.1219
16. Burkin, D. J., and Kaufman, S. J. (1999). The alpha7beta1 integrin in muscle development and disease. Cell Tissue Res. 296, 183-190. doi: 10.1007/s004410051279
17. Castillero, E., Nieto-Bona, M. P., Fernandez-Galaz, C., Martin, A. I., Lopez-Menduina, M., et al. (2011). Fenofibrate, a PPARα agonist, decreases atrogenes and myostatin expression and improves arthritis-induced skeletal muscle atrophy. Am. J. Physiol. Endocrinol. Metab. 300, E790-E799. doi: 10.1152/ajpendo.00590.2010
18. Cerletti, M., Jurga, S., Witczak, C. A., Hirshman, M. F., Shadrach, J. L., Goodyear, L. J., et al. (2008). Highly efficient, functional engraftment of skeletal muscle stem cells in dystrophic muscles. Cell 134, 37-47. doi: 10.1016/j.cell.2008.05.049
19. Cerletti, M., Negri, T., Cozzi, F., Colpo, R., Andreetta, F., Croci, D., et al. (2003). Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer. Gene Ther. 10, 750-757. doi: 10.1038/sj.gt.3301941
20. Chen, J. F., Mandel, E. M., Thomson, J. M., Wu, Q. L., Callis, T. E., Hammond, S. M., et al. (2006). The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat. Genet. 38, 228-233. doi: 10.1038/Ng1725
21. Clop, A., Marcq, F., Takeda, H., Pirottin, D., Tordoir, X., Bibe, B., et al. (2006). A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat. Genet. 38, 813-818. doi: 10.1038/ng1810
22. Cornelison, D. D., Wilcox-Adelman, S. A., Goetinck, P. F., Rauvala, H., Rapraeger, A. C., and Olwin, B. B. (2004). Essential and separable roles for Syndecan-3 and Syndecan-4 in skeletal muscle development and regeneration. Genes Dev. 18, 2231-2236. doi: 10.1101/gad.1214204
23. Cottard, V., Mulleman, D., Bouille, P., Mezzina, M., Boissier, M. C., and Bessis, N. (2000). Adeno-associated virus-mediated delivery of IL-4 prevents collagen-induced arthritis. Gene Ther. 7, 1930-1939. doi: 10.1038/sj.gt.3301324
24. Cozzoli, A., Rolland, J. F., Capogrosso, R. F., Sblendorio, V. T., Longo, V., Simonetti, S., et al. (2011). Evaluation of potential synergistic action of a combined treatment with alpha-methyl-prednisolone and taurine on the mdx mouse model of Duchenne muscular dystrophy. Neuropathol. Appl. Neurobiol. 37, 243-256. doi: 10.1111/j.1365-2990.2010.01106.x
25. Crippa, S., Cassano, M., Messina, G., Galli, D., Galvez, B. G., Curk, T., et al. (2011). miR669a and miR669q prevent skeletal muscle differentiation in postnatal cardiac progenitors. J. Cell Biol. 193, 1197-1212. doi: 10.1083/jcb.201011099
26. Crippa, S., Cassano, M., and Sampaolesi, M. (2012). Role of miRNAs in muscle stem cell biology: proliferation, differentiation and death. Curr. Pharm. Des. 18, 1718-1729. doi: 10.2174/138161212799859620
27. Crist, C. G., Montarras, D., Pallafacchina, G., Rocancourt, D., Cumano, A., Conway, S. J., et al. (2009). Muscle stem cell behavior is modified by microRNA-27 regulation of Pax3 expression. Proc. Natl. Acad. Sci. U.S.A. 106, 13383-13387. doi: 10.1073/pnas.0900210106
28. Dai, J., and Rabie, A. B. M. (2007). The use of recombinant adeno-associated virus for skeletal gene therapy. Orthod. Craniofac. Res. 10, 1-14. doi: 10.1111/j.1601-6343.2007.00381.x
29. D'Angelo, M. G., Gandossini, S., Martinelli Boneschi, F., Sciorati, C., Bonato, S., Brighina, E., et al. (2012). Nitric oxide donor and non steroidal anti inflammatory drugs as a therapy for muscular dystrophies: evidence from a safety study with pilot efficacy measures in adult dystrophic patients. Pharmacol. Res 65, 472-479. doi: 10.1016/j.phrs.2012.01.006
30. Darabi, R., Arpke, R. W., Irion, S., Dimos, J. T., Grskovic, M., Kyba, M., et al. (2012). Human ES- and iPS-derived myogenic progenitors restore DYSTROPHIN and improve contractility upon transplantation in dystrophic mice. Cell Stem Cell 10, 610-619. doi: 10.1016/j.stem.2012.02.015
31. Darabi, R., Pan, W., Bosnakovski, D., Baik, J., Kyba, M., and Perlingeiro, R. C. (2011). Functional myogenic engraftment from mouse iPS cells. Stem Cell Rev. 7, 948-957. doi: 10.1007/s12015-011-9258-2
32. Djuranovic, S., Nahvi, A., and Green, R. (2011). A parsimonious model for gene regulation by miRNAs. Science 331, 550-553. doi: 10.1126/science.1191138
33. Douglas, A. G., and Wood, M. J. (2013). Splicing therapy for neuromuscular disease. Mol. Cell. Neurosci. 56, 169-185. doi: 10.1016/j.mcn.2013.04.005
34. Eisenberg, I., Eran, A., Nishino, I., Moggio, M., Lamperti, C., Amato, A. A., et al. (2007). Distinctive patterns of microRNA expression in primary muscular disorders. Proc. Natl. Acad. Sci. U.S.A. 104, 17016-17021. doi: 10.1073/pnas.0708115104
35. Emery, A. E. H. (2002). The muscular dystrophies. Lancet 359, 687-695. doi: 10.1016/S0140-6736(02)07815-7
36. Evans, M. J., and Kaufman, M. H. (1981). Establishment in culture of pluripotential cells from mouse embryos. Nature 292, 154-156. doi: 10.1038/292154a0
37. Fearon, K., Strasser, F., Anker, S. D., Bosaeus, I., Bruera, E., Fainsinger, R. L., et al. (2011). Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12, 489-495. doi: 10.1016/S1470-2045(10)70218-7
38. Filareto, A., Darabi, R., and Perlingeiro, R. C. (2012). Engraftment of ES-derived myogenic progenitors in a severe mouse model of muscular dystrophy. J. Stem Cell Res. Ther. 10:S10-001. doi: 10.4172/2157-7633.S10-001
39. Filareto, A., Parker, S., Darabi, R., Borges, L., Iacovino, M., Schaaf, T., et al. (2013). An ex vivo gene therapy approach to treat muscular dystrophy using inducible pluripotent stem cells. Nat. Commun. 4, 1549. doi: 10.1038/ncomms2550
40. Finkel, R. S. (2010). Read-through strategies for suppression of nonsense mutations in Duchenne/Becker muscular dystrophy: aminoglycosides and ataluren (PTC124). J. Child Neurol. 25, 1158-1164. doi: 10.1177/0883073810371129
41. Ge, Y., and Chen, J. (2011). MicroRNAs in skeletal myogenesis. Cell Cycle 10, 441-448. doi: 10.4161/cc.10.3.14710
42. Gilbert, R., Nalbantoglu, J., Petrof, B. J., Ebihara, S., Guibinga, G. H., Tinsley, J. M., et al. (1999). Adenovirus-mediated utrophin gene transfer mitigates the dystrophic phenotype of mdx mouse muscles. Hum. Gene Ther. 10, 1299-1310. doi: 10.1089/10430349950017987
43. Gnocchi, V. F., White, R. B., Ono, Y., Ellis, J. A., and Zammit, P. S. (2009). Further characterisation of the molecular signature of quiescent and activated mouse muscle satellite cells. PLoS ONE 4:E5205. doi: 10.1371/Journal.Pone.0005205
44. Goldstein, J. A., and Mcnally, E. M. (2010). Mechanisms of muscle weakness in muscular dystrophy. J. Gen. Physiol. 136, 29-34. doi: 10.1085/jgp.201010436
45. Gomes, M. D., Lecker, S. H., Jagoe, R. T., Navon, A., and Goldberg, A. L. (2001). Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc. Natl. Acad. Sci. U.S.A. 98, 14440-14445. doi: 10.1073/pnas.251541198
46. Gomez-Sanmiguel, A. B., Martin, A. I., Nieto-Bona, M. P., Fernandez-Galaz, C., Lopez-Menduina, M., Villanua, M. A., et al. (2013). Systemic alpha-melanocyte-stimulating hormone administration decreases arthritis-induced anorexia and muscle wasting. Am. J. Physiol. Regul. Integr. Comp. Physiol. 304, R877-R886. doi: 10.1152/ajpregu.00447.2012
47. Goonasekera, S. A., Lam, C. K., Millay, D. P., Sargent, M. A., Hajjar, R. J., Kranias, E. G., et al. (2011). Mitigation of muscular dystrophy in mice by SERCA overexpression in skeletal muscle. J. Clin. Invest. 121, 1044-1052. doi: 10.1172/JCI43844
48. Goudenege, S., Lebel, C., Huot, N. B., Dufour, C., Fujii, I., Gekas, J., et al. (2012). Myoblasts derived from normal hESCs and dystrophic hiPSCs efficiently fuse with existing muscle fibers following transplantation. Mol. Ther. 20, 2153-2167. doi: 10.1038/mt.2012.188
49. Goyenvalle, A., Wright, J., Babbs, A., Wilkins, V., Garcia, L., and Davies, K. E. (2012). Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy. Mol. Ther. 20, 1212-1221. doi: 10.1038/mt.2012.26
50. Gregorevic, P., Allen, J. M., Minami, E., Blankinship, M. J., Haraguchi, M., Meuse, L., et al. (2006). rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat. Med. 12, 787-789. doi: 10.1038/nm1439
51. Gregorevic, P., Blankinship, M. J., Allen, J. M., Crawford, R. W., Meuse, L., Miller, D. G., et al. (2004). Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat. Med. 10, 828-834. doi: 10.1038/nm1085
52. Griggs, R. C., Moxley, R. T. 3rd. Mendell, J. R., Fenichel, G. M., Brooke, M. H., Pestronk, A., et al. (1991). Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch. Neurol. 48, 383-388. doi: 10.1001/archneur.1991.00530160047012
53. Griggs, R. C., Moxley, R. T. 3rd. Mendell, J. R., Fenichel, G. M., Brooke, M. H., Pestronk, A., et al. (1993). Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 43, 520-527. doi: 10.1212/WNL.43.3_Part_1.520
54. Gros, J., Manceau, M., Thome, V., and Marcelle, C. (2005). A common somitic origin for embryonic muscle progenitors and satellite cells. Nature 435, 954-958. doi: 10.1038/Nature03572
55. Gueta, I., Altman, A., and Shoenfeld, Y. (2010). [The effect of blocking TNF-alpha in patients with cancer-related cachexia and anorexia]. Harefuah 149, 512-514, 550, 551.
56. Gumerson, J. D., and Michele, D. E. (2011). The dystrophin-glycoprotein complex in the prevention of muscle damage. J. Biomed. Biotechnol. 2011:210797. doi: 10.1155/2011/210797
57. Gussoni, E., Soneoka, Y., Strickland, C. D., Buzney, E. A., Khan, M. K., Flint, A. F., et al. (1999). Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature 401, 390-394. doi: 10.1038/43922
58. Ham, D. J., Murphy, K. T., Chee, A., Lynch, G. S., and Koopman, R. (2013). Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia. Clin. Nutr. doi: 10.1016/j.clnu.2013.06.013. [Epub ahead of print].
59. Hamed, S. A. (2006). Drug evaluation: PTC-124-a potential treatment of cystic fibrosis and Duchenne muscular dystrophy. IDrugs 9, 783-789.
60. He, W. A., Berardi, E., Cardillo, V. M., Acharyya, S., Aulino, P., Thomas-Ahner, J., et al. (2013). NF-κB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. J. Clin. Invest. 123, 4821-4835. doi: 10.1172/JCI68523
61. Hill, E., Boontheekul, T., and Mooney, D. J. (2006). Designing scaffolds to enhance transplanted myoblast survival and migration. Tissue Eng. 12, 1295-1304. doi: 10.1089/ten.2006.12.1295
62. Huard, J., Li, Y., and Fu, F. H. (2002). Current concepts review - Muscle injuries and repair: current trends in research. J. Bone Joint Surg. Am. 84A, 822-832.
63. Irintchev, A., Zeschnigk, M., Starzinski-Powitz, A., and Wernig, A. (1994). Expression pattern of M-cadherin in normal, denervated, and regenerating mouse muscles. Dev. Dyn. 199, 326-337. doi: 10.1002/aja.1001990407
64. Jarvinen, T. A. H. J., Jarvinen, T. L. N., Kaariainen, M., Kalimo, A., and Jarvinen, M. (2005). Muscle injuries - Biology and treatment. Am. J. Sports Med. 33, 745-764. doi: 10.1177/0363546505274714
65. Jensen, T. E., and Richter, E. A. (2012). Regulation of glucose and glycogen metabolism during and after exercise. J. Physiol. 590, 1069-1076. doi: 10.1113/jphysiol.2011.224972
66. Jorgensen, L. H., Larochelle, N., Orlopp, K., Dunant, P., Dudley, R. W., Stucka, R., et al. (2009). Efficient and fast functional screening of microdystrophin constructs in vivo and in vitro for therapy of duchenne muscular dystrophy. Hum. Gene Ther. 20, 641-650. doi: 10.1089/hum.2008.162
67. Kassar-Duchossoy, L., Giacone, E., Gayraud-Morel, B., Jory, A., Gomes, D., and Tajbakhsh, S. (2005). Pax3/Pax7 mark a novel population of primitive myogenic cells during development. Genes Dev. 19, 1426-1431. doi: 10.1101/Gad.345505
68. Katakura, S., Jennings, K., Watanabe, S., Adachi, E., Thornton, S., Gao, G. P., et al. (2004). Recombinant adeno-associated virus preferentially transduces human, compared to mouse, synovium: implications for arthritis therapy. Mod. Rheumatol. 14, 18-24. doi: 10.1007/s10165-003-0260-7
69. Kayali, R., Ku, J. M., Khitrov, G., Jung, M. E., Prikhodko, O., and Bertoni, C. (2012). Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy. Hum. Mol. Genet. 21, 4007-4020. doi: 10.1093/hmg/dds223
70. Kim, H. K., Lee, Y. S., Sivaprasad, U., Malhotra, A., and Dutta, A. (2006). Muscle-specific microRNA miR-206 promotes muscle differentiation. J. Cell Biol. 174, 677-687. doi: 10.1083/jcb.200603008
71. Kim, K., Doi, A., Wen, B., Ng, K., Zhao, R., Cahan, P., et al. (2010). Epigenetic memory in induced pluripotent stem cells. Nature 467, 285-290. doi: 10.1038/nature09342
72. Kinali, M., Arechavala-Gomeza, V., Feng, L., Cirak, S., Hunt, D., Adkin, C., et al. (2009). Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 8, 918-928. doi: 10.1016/S1474-4422(09)70211-X
73. Koo, T., Okada, T., Athanasopoulos, T., Foster, H., Takeda, S., and Dickson, G. (2011). Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog. J. gene Med. 13, 497-506. doi: 10.1002/jgm.1602
74. Kuang, S., and Rudnicki, M. A. (2008). The emerging biology of satellite cells and their therapeutic potential. Trends Mol. Med. 14, 82-91. doi: 10.1016/j.molmed.2007.12.004
75. Laviano, A., Meguid, M. M., and Rossi-Fanelli, F. (2003). Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. Lancet Oncol. 4, 686-694. doi: 10.1016/S1470-2045(03)01247-6
76. Lee, R. C., Feinbaum, R. L., and Ambros, V. (1993). The c-elegans heterochronic gene lin-4 encodes small rnas with antisense complementarity to lin-14. Cell 75, 843-854. doi: 10.1016/0092-8674(93)90529-Y
77. Leung, D. G., and Wagner, K. R. (2013). Therapeutic advances in muscular dystrophy. Ann. Neurol. 74, 404-411. doi: 10.1002/Ana.23989
78. Lim, S. S., Vos, T., Flaxman, A. D., Danaei, G., Shibuya, K., Adair-Rohani, H., et al. (2012). A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2224-2260. doi: 10.1016/S0140-6736(12)61766-8
79. Liu, M., Yue, Y., Harper, S. Q., Grange, R. W., Chamberlain, J. S., and Duan, D. (2005). Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury. Mol. Ther. 11, 245-256. doi: 10.1016/j.ymthe.2004.09.013
80. Malafarina, V., Uriz-Otano, F., Iniesta, R., and Gil-Guerrero, L. (2012). Sarcopenia in the elderly: diagnosis, physiopathology and treatment. Maturitas 71, 109-114. doi: 10.1016/j.maturitas.2011.11.012
81. Marcora, S. M., Chester, K. R., Mittal, G., Lemmey, A. B., and Maddison, P. J. (2006). Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am. J. Clin. Nutr. 84, 1463-1472.
82. Martin, G. R. (1981). Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc. Natl. Acad. Sci. U.S.A. 78, 7634-7638. doi: 10.1073/pnas.78.12.7634
83. Mauro, A. (1961). Satellite cell of skeletal muscle fibers. J. Biophys. Biochem. Cytol. 9, 493-495. doi: 10.1083/jcb.9.2.493
84. McClorey, G., Moulton, H. M., Iversen, P. L., Fletcher, S., and Wilton, S. D. (2006). Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther. 13, 1373-1381. doi: 10.1038/sj.gt.3302800
85. Meech, R., Gonzalez, K. N., Barro, M., Gromova, A., Zhuang, L., Hulin, J. A., et al. (2012). Barx2 is expressed in satellite cells and is required for normal muscle growth and regeneration. Stem Cells 30, 253-265. doi: 10.1002/stem.777
86. Minasi, M. G., Riminucci, M., De Angelis, L., Borello, U., Berarducci, B., Innocenzi, A., et al. (2002). The meso-angioblast: a multipotent, self-renewing cell that originates from the dorsal aorta and differentiates into most mesodermal tissues. Development 129, 2773-2784.
87. Minetti, G. C., Colussi, C., Adami, R., Serra, C., Mozzetta, C., Parente, V., et al. (2006). Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat. Med. 12, 1147-1150. doi: 10.1038/Nm1479
88. Mizuno, Y., Chang, H., Umeda, K., Niwa, A., Iwasa, T., Awaya, T., et al. (2010). Generation of skeletal muscle stem/progenitor cells from murine induced pluripotent stem cells. FASEB J. 24, 2245-2253. doi: 10.1096/fj.09-137174
89. Montanaro, F., Liadaki, K., Schienda, J., Flint, A., Gussoni, E., and Kunkel, L. M. (2004). Demystifying SP cell purification: viability, yield, and phenotype are defined by isolation parameters. Exp. Cell Res. 298, 144-154. doi: 10.1016/j.yexcr.2004.04.010
90. Montarras, D., Morgan, J., Collins, C., Relaix, F., Zaffran, S., Cumano, A., et al. (2005). Direct isolation of satellite cells for skeletal muscle regeneration. Science 309, 2064-2067. doi: 10.1126/science.1114758
91. Moorwood, C., Lozynska, O., Suri, N., Napper, A. D., Diamond, S. L., and Khurana, T. S. (2011). Drug discovery for Duchenne muscular dystrophy via utrophin promoter activation screening. PLoS ONE 6:e26169. doi: 10.1371/journal.pone.0026169
92. Morgan, C. L., Emery, P., Porter, D., Reynolds, A., Young, A., Boyd, H., et al. (2014). Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data. Rheumatology 53, 186-194. doi: 10.1093/rheumatology/ket333
93. Morine, K. J., Bish, L. T., Pendrak, K., Sleeper, M. M., Barton, E. R., and Sweeney, H. L. (2010). Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice. PLoS ONE 5:e9176. doi: 10.1371/journal.pone.0009176
94. Mouly, V., Aamiri, A., Perie, S., Mamchaoui, K., Barani, A., Bigot, A., et al. (2005). Myoblast transfer therapy: is there any light at the end of the tunnel? Acta Myol. 24, 128-133.
95. Moxley, R. T. 3rd. Ashwal, S., Pandya, S., Connolly, A., Florence, J., Mathews, K., et al. (2005). Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 64, 13-20. doi: 10.1212/01.WNL.0000148485.00049.B7
96. Mozzetta, C., Consalvi, S., Saccone, V., Tierney, M., Diamantini, A., Mitchell, K. J., et al. (2013). Fibroadipogenic progenitors mediate the ability of HDAC inhibitors to promote regeneration in dystrophic muscles of young, but not old Mdx mice. EMBO Mol. Med. 5, 626-639. doi: 10.1002/emmm.201202096
97. Nai, Y. J., Jiang, Z. W., Wang, Z. M., Li, N., and Li, J. S. (2007). Prevention of cancer cachexia by pyrrolidine dithiocarbamate (PDTC) in colon 26 tumor-bearing mice. JPEN 31, 18-25. doi: 10.1177/014860710703100118
98. Nielsen, S., and Pedersen, B. K. (2008). Skeletal muscle as an immunogenic organ. Curr. Opin. Pharmacol. 8, 346-351. doi: 10.1016/j.coph.2008.02.005
99. Nudelman, I., Rebibo-Sabbah, A., Cherniavsky, M., Belakhov, V., Hainrichson, M., Chen, F., et al. (2009). Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations. J. Med. Chem. 52, 2836-2845. doi: 10.1021/jm801640k
100. Obokata, H., Wakayama, T., Sasai, Y., Kojima, K., Vacanti, M. P., Niwa, H., et al. (2014). Stimulus-triggered fate conversion of somatic cells into pluripotency. Nature 505, 641-647. doi: 10.1038/nature12968
101. Okada, M., Payne, T. R., Zheng, B., Oshima, H., Momoi, N., Tobita, K., et al. (2008). Myogenic endothelial cells purified from human skeletal muscle improve cardiac function after transplantation into infarcted myocardium. J. Am. Coll. Cardiol. 52, 1869-1880. doi: 10.1016/j.jacc.2008.07.064
102. Palus, S., Von Haehling, S., Flach, V. C., Tschirner, A., Doehner, W., Anker, S. D., et al. (2013). Simvastatin reduces wasting and improves cardiac function as well as outcome in experimental cancer cachexia. Int. J. Cardiol. 168, 3412-3418. doi: 10.1016/j.ijcard.2013.04.150
103. Partridge, T. A., Morgan, J. E., Coulton, G. R., Hoffman, E. P., and Kunkel, L. M. (1989). Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts. Nature 337, 176-179. doi: 10.1038/337176a0
104. Pedersen, B. K., and Febbraio, M. A. (2008). Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol. Rev. 88, 1379-1406. doi: 10.1152/physrev.90100.2007
105. Perez, A. L., Bachrach, E., Illigens, B. M. W., Jun, S. J., Bagden, E., Steffen, L., et al. (2009). Cxcr4 enhances engraftment of muscle progenitor cells. Muscle Nerve 40, 562-572. doi: 10.1002/Mus.21317
106. Polesskaya, A., Seale, P., and Rudnicki, M. A. (2003). Wnt signaling induces the myogenic specification of resident CD45(+) adult stem cells during muscle regeneration. Cell 113, 841-852. doi: 10.1016/S0092-8674(03)00437-9
107. Politano, L., Nigro, G., Nigro, V., Piluso, G., Papparella, S., Paciello, O., et al. (2003). Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol. 22, 15-21.
108. Polo, J. M., Liu, S., Figueroa, M. E., Kulalert, W., Eminli, S., Tan, K. Y., et al. (2010). Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat. Biotechnol. 28, 848-855. doi: 10.1038/nbt.1667
109. Qiao, C., Li, J., Jiang, J., Zhu, X., Wang, B., and Xiao, X. (2008). Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice. Hum. Gene Ther. 19, 241-254. doi: 10.1089/hum.2007.159
110. Qiao, C., Li, J., Zheng, H., Bogan, J., Yuan, Z., Zhang, C., et al. (2009). Hydrodynamic limb vein injection of adeno-associated virus serotype 8 vector carrying canine myostatin propeptide gene into normal dogs enhances muscle growth. Hum. Gene Ther. 20, 1-10. doi: 10.1089/hum.2008.135
111. Quattrocelli, M., Crippa, S., Montecchiani, C., Camps, J., Cornaglia, A. I., Boldrin, L., et al. (2013). Long-term miR-669a therapy alleviates chronic dilated cardiomyopathy in dystrophic mice. J. Am. Heart Assoc. 2:e000284. doi: 10.1161/JAHA.113.000284
112. Quattrocelli, M., Palazzolo, G., Floris, G., Schöffski, P., Anastasia, L., Orlacchio, A., et al. (2011). Intrinsic cell memory reinforces myogenic commitment of pericyte-derived iPSCs. J. Pathol. 223, 593-603. doi: 10.1002/path.2845
113. Quattrocelli, M., Palazzolo, G., Perini, I., Crippa, S., Cassano, M., and Sampaolesi, M. (2012). Mouse and human mesoangioblasts: isolation and characterization from adult skeletal muscles. Methods Mol. Biol. 798, 65-76. doi: 10.1007/978-1-61779-343-1_4
114. Ratajczak, M. Z., Majka, M., Kucia, M., Drukala, J., Pietrzkowski, Z., Peiper, S., et al. (2003). Expression of functional CXCR4 by muscle satellite cells and secretion of SDF-1 by muscle-derived fibroblasts is associated with the presence of both muscle progenitors in bone marrow and hematopoietic stem/progenitor cells in muscles. Stem Cells 21, 363-371. doi: 10.1634/stemcells.21-3-363
115. Relaix, F., Rocancourt, D., Mansouri, A., and Buckingham, M. (2005). A Pax3/Pax7-dependent population of skeletal muscle progenitor cells. Nature 435, 948-953. doi: 10.1038/Nature03594
116. Rinaldi, F., and Perlingeiro, R. C. (2013). Stem cells for skeletal muscle regeneration: therapeutic potential and roadblocks. Transl. Res. doi: 10.1016/j.trsl.2013.11.006. [Epub ahead of print].
117. Rodino-Klapac, L. R., Janssen, P. M., Montgomery, C. L., Coley, B. D., Chicoine, L. G., Clark, K. R., et al. (2007). A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy. J. Trans. Med. 5:45. doi: 10.1186/1479-5876-5-45
118. Rodino-Klapac, L. R., Janssen, P. M., Shontz, K. M., Canan, B., Montgomery, C. L., Griffin, D., et al. (2013). Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model. Hum. Mol. Genet. 22, 4929-4937. doi: 10.1093/hmg/ddt342
119. Rosenberg, M. I., Georges, S. A., Asawachaicharn, A., Analau, E., and Tapscott, S. J. (2006). MyoD inhibits Fstl1 and Utrn expression by inducing transcription of miR-206. J. Cell Biol. 175, 77-85. doi: 10.1083/jcb.200603039
120. Ruegg, U. T., Nicolas-Metral, V., Challet, C., Bernard-Helary, K., Dorchies, O. M., Wagner, S., et al. (2002). Pharmacological control of cellular calcium handling in dystrophic skeletal muscle. Neuromuscul. Disord. 12(Suppl. 1), S155-S161. doi: 10.1016/S0960-8966(02)00095-0
121. Sacco, A., Doyonnas, R., Kraft, P., Vitorovic, S., and Blau, H. M. (2008). Self-renewal and expansion of single transplanted muscle stem cells. Nature 456, 502-506. doi: 10.1038/Nature07384
122. Sampaolesi, M., Blot, S., D'Antona, G., Granger, N., Tonlorenzi, R., Innocenzi, A., et al. (2006). Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 444, 574-579. doi: 10.1038/nature05282
123. Sampaolesi, M., Torrente, Y., Innocenzi, A., Tonlorenzi, R., D'Antona, G., Pellegrino, M. A., et al. (2003). Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science 301, 487-492. doi: 10.1126/science.1082254
124. Scott, D., Blizzard, L., Fell, J., and Jones, G. (2011). The epidemiology of sarcopenia in community living older adults: what role does lifestyle play? J. Cachexia Sarcopenia Muscle 2, 125-134. doi: 10.1007/s13539-011-0036-4
125. Seale, P., Ishibashi, J., Scime, A., and Rudnicki, M. A. (2004). Pax7 is necessary and sufficient for the myogenic specification of CD45(+): Sca1(+) stem cells from injured muscle. PLoS Biol. 2:e130. doi: 10.1371/journal.pbio.0020130
126. Sherwood, R. I., Christensen, J. L., Conboy, I. M., Conboy, M. J., Rando, T. A., Weissman, I. L., et al. (2004). Isolation of adult mouse myogenic progenitors: Functional heterogeneity of cells within and engrafting skeletal muscle. Cell 119, 543-554. doi: 10.1016/j.cell.2004.10.021
127. Skuk, D., and Tremblay, J. P. (2011). Intramuscular cell transplantation as a potential treatment of myopathies: clinical and preclinical relevant data. Exp. Opin. Biol. Ther. 11, 359-374. doi: 10.1517/14712598.2011.548800
128. Small, E. M., O'Rourke, J. R., Moresi, V., Sutherland, L. B., McAnally, J., Gerard, R. D., et al. (2010). Regulation of PI3-kinase/Akt signaling by muscle-enriched microRNA-486. Proc. Natl. Acad. Sci. U.S.A. 107, 4218-4223. doi: 10.1073/pnas.1000300107
129. Suzuki, H., Asakawa, A., Amitani, H., Nakamura, N., and Inui, A. (2013). Cancer cachexia-pathophysiology and management. J. Gastroenterol. 48, 574-594. doi: 10.1007/s00535-013-0787-0
130. Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676. doi: 10.1016/j.cell.2006.07.024
131. Tamaki, T., Akatsuka, A., Ando, K., Nakamura, Y., Matsuzawa, H., Hotta, T., et al. (2002). Identification of myogenic-endothelial progenitor cells in the interstitial spaces of skeletal muscle. J. Cell Biol. 157, 571-577. doi: 10.1083/jcb.200112106
132. Tanaka, K. K., Hall, J. K., Troy, A. A., Cornelison, D. D. W., Majka, S. M., and Olwin, B. B. (2009). Syndecan-4-expressing muscle progenitor cells in the SP engraft as satellite cells during muscle regeneration. Cell Stem Cell 4, 217-225. doi: 10.1016/j.stem.2009.01.016
133. Tedesco, F. S., Dellavalle, A., Diaz-Manera, J., Messina, G., and Cossu, G. (2010). Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells. J. Clin. Invest. 120, 11-19. doi: 10.1172/JCI40373
134. Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. S., et al. (1998). Embryonic stem cell lines derived from human blastocysts. Science 282, 1145-1147. doi: 10.1126/science.282.5391.1145
135. Tinsley, J., Deconinck, N., Fisher, R., Kahn, D., Phelps, S., Gillis, J. M., et al. (1998). Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat. Med. 4, 1441-1444. doi: 10.1038/4033
136. Tisdale, M. J. (2002). Cachexia in cancer patients. Nat. Rev. Cancer 2, 862-871. doi: 10.1038/nrc927
137. Todorov, P., Cariuk, P., McDevitt, T., Coles, B., Fearon, K., and Tisdale, M. (1996). Characterization of a cancer cachectic factor. Nature 379, 739-742. doi: 10.1038/379739a0
138. Todorov, P. T., Field, W. N., and Tisdale, M. J. (1999). Role of a proteolysis-inducing factor (PIF) in cachexia induced by a human melanoma (G361). Br. J. Cancer 80, 1734-1737. doi: 10.1038/sj.bjc.6690590
139. Tonlorenzi, R., Dellavalle, A., Schnapp, E., Cossu, G., and Sampaolesi, M. (2007). Isolation and characterization of mesoangioblasts from mouse, dog, and human tissues. Curr. Protoc. Stem Cell Biol. Chapter 2: Unit 2B.1. doi: 10.1002/9780470151808.sc02b01s3
140. Twayana, S., Legnini, I., Cesana, M., Cacchiarelli, D., Morlando, M., and Bozzoni, I. (2013). Biogenesis and function of non-coding RNAs in muscle differentiation and in Duchenne muscular dystrophy. Biochem. Soc. Trans. 41, 844-849. doi: 10.1042/BST20120353
141. Van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W. S., Aartsma-Rus, A., Bremmer-Bout, M., et al. (2007). Local dystrophin restoration with antisense oligonucleotide PRO051. N. Engl. J. Med. 357, 2677-2686. doi: 10.1056/NEJMoa073108
142. Van Rooij, E., Liu, N., and Olson, E. N. (2008). MicroRNAs flex their muscles. Trends Genet. 24, 159-166. doi: 10.1016/j.tig.2008.01.007
143. Van Rooij, E., Quiat, D., Johnson, B. A., Sutherland, L. B., Qi, X. X., Richardson, J. A., et al. (2009). A Family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev. Cell 17, 662-673. doi: 10.1016/j.devcel.2009.10.013
144. Vaughan, V. C., Sullivan-Gunn, M., Hinch, E., Martin, P., and Lewandowski, P. A. (2012). Eicosapentaenoic acid and oxypurinol in the treatment of muscle wasting in a mouse model of cancer cachexia. PLoS ONE 7:e45900. doi: 10.1371/journal.pone.0045900
145. Volonte, D., Liu, Y., and Galbiati, F. (2005). The modulation of caveolin-1 expression controls satellite cell activation during muscle repair. FASEB J. 19, 237-239. doi: 10.1096/fj.04-2215fje
146. Wang, Y. X., and Rudnicki, M. A. (2012). Satellite cells, the engines of muscle repair. Nature Rev. Mol. Cell Biol. 13, 127-133. doi: 10.1038/nrm3265
147. Wightman, B., Ha, I., and Ruvkun, G. (1993). Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75, 855-862. doi: 10.1016/0092-8674(93)90530-4
148. Wu, C., Fernandez, S. A., Criswell, T., Chidiac, T. A., Guttridge, D., Villalona-Calero, M., et al. (2013). Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease. Pancreas 42, 813-818. doi: 10.1097/MPA.0b013e318279b87f
149. Yoshimura, M., Sakamoto, M., Ikemoto, M., Mochizuki, Y., Yuasa, K., Miyagoe-Suzuki, Y., et al. (2004). AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype. Mol. Ther. 10, 821-828. doi: 10.1016/j.ymthe.2004.07.025
150. Zhang, L., Tang, H., Kou, Y., Li, R., Zheng, Y., Wang, Q., et al. (2013). MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia. J. Cancer Res. Clin. Oncol. 139, 1105-1115. doi: 10.1007/s00432-013-1412-6
151. Zhou, W., Jiang, Z. W., Tian, J., Jiang, J., Li, N., and Li, J. S. (2003). Role of NF-kappaB and cytokine in experimental cancer cachexia. World J. Gastroenterol. 9, 1567-1570.